Advanced Androgen-Independent Prostate Cancer
Showing 1 - 25 of >10,000
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,
Not yet recruiting
- Androgen-Independent Prostatic Cancer
- +8 more
- lorigerlimab
- +2 more
- (no location specified)
May 4, 2023
Prostate Cancer, Malignant Tumor of Prostate, Secondary Malignant Tumor of Prostate Trial in Cleveland (drug, other, radiation)
Not yet recruiting
- Prostate Cancer
- +2 more
- Androgen deprivation therapy (ADT)
- +3 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center Seidman Cancer Cen
Nov 21, 2023
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer Trial in Oklahoma City (Relugolix and Enzalutamide)
Not yet recruiting
- Androgen Deprivation Therapy
- Locally Advanced Prostate Cancer
- Relugolix and Enzalutamide
-
Oklahoma City, OklahomaStephenson Cancer Center at OU Health, University of Oklahoma He
Nov 8, 2023
Prostate Cancer Trial in Cincinnati (Apalutamide Oral Product, Androgen Deprivation Therapy (ADT), Focal Therapy)
Not yet recruiting
- Prostate Cancer
- Apalutamide Oral Product
- +2 more
-
Cincinnati, OhioUniversity of Cincinnati Medical Center
Mar 27, 2023
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer Trial in
Recruiting
- Castration-Resistant Prostatic Cancer
- +4 more
- ARAT
- +2 more
-
Orange City, Florida
- +1 more
Nov 23, 2022
Physical Function During ARSI Treatment
Recruiting
- Advanced Prostate Carcinoma
- androgen receptor signaling inhibitors
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 Trial in Houston (drug, procedure,
Recruiting
- Prostate Carcinoma
- +6 more
- Abiraterone Acetate
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Radiotherapy and Androgen Deprivation In Combination After Local
Not yet recruiting
- Prostate Cancer
- Luteinising Hormone-Releasing Factor Analogue
- (no location specified)
Nov 16, 2023
Prostate Cancer Trial in Birmingham (Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation
Recruiting
- Prostate Cancer
- Abemaciclib 150 MG by mouth twice daily
- +2 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham (UAB)
Mar 18, 2022
Prostate Cancer Trial in Ann Arbor, Seattle (Aplidin (plitidepsin))
Terminated
- Prostate Cancer
- Aplidin (plitidepsin)
-
Ann Arbor, Michigan
- +1 more
Nov 16, 2020
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Castration-resistant Prostate Cancer, Homologous Recombination Deficiency Trial in Sydney (Testosterone Enanthate 100 MG/ML
Recruiting
- Castration-resistant Prostate Cancer
- Homologous Recombination Deficiency
- Testosterone Enanthate 100 MG/ML Injectable Solution
- Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
-
Sydney, New South Wales, AustraliaKinghorn Cancer Centre, St. Vincent's Hospital
Dec 16, 2022
Prostate Cancer Trial in Louisville (Taxotere, Doxil)
Completed
- Prostate Cancer
-
Louisville, KentuckyJames Graham Brown Cancer Center
Oct 29, 2019
Metastatic Castration-resistant Prostate Cancer Trial in New Haven (Testosterone Cypionate, Sipuleucel-T)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Testosterone Cypionate
- Sipuleucel-T
-
New Haven, ConnecticutYale Cancer Center
Oct 20, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +3 more
- (no location specified)
Jan 23, 2023
Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 12, 2023
Prostate Cancer Trial in Atlanta (Genistein, Placebo)
Adenocarcinoma of the Prostate Trial in Washington, Baltimore, Bethesda (Radiation Therapy, Androgen Deprivation Therapy (ADT))
Active, not recruiting
- Adenocarcinoma of the Prostate
- Radiation Therapy
- Androgen Deprivation Therapy (ADT)
-
Washington, District of Columbia
- +2 more
Oct 25, 2022
Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor
Not yet recruiting
- Androgen Deprivation Therapy
- +4 more
- Gonadotropin-Releasing Hormone Agonist
- +2 more
- (no location specified)
Jan 18, 2023
Prostate Cancer Trial in San Francisco (STAND-T platform, Survey Administration, Text Messages)
Recruiting
- Prostate Cancer
- STAND-T platform
- +2 more
-
San Francisco, California
- +1 more
Oct 26, 2022
Prostate Cancer Trial in Philadelphia (docetaxel, sorafenib tosylate)
Completed
- Prostate Cancer
- docetaxel
- sorafenib tosylate
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Feb 16, 2022
Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic Trial in Boston (Aerobic and resistance exercise,
Recruiting
- Androgen Deprivation Therapy
- +2 more
- Aerobic and resistance exercise
- Usual Care
-
Boston, MassachusettsDana Farber Cancer Institute
Oct 4, 2022
Advanced Prostate Cancer Trial in Hong Kong (Conventional IMRT, SBRT)
Recruiting
- Advanced Prostate Cancer
- Conventional IMRT
- SBRT
-
Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital
Sep 13, 2022
Advanced Prostate Cancer Trial in United Kingdom, United States (HPN424)
Active, not recruiting
- Advanced Prostate Cancer
- HPN424 In Part 1 (Dose Escalation)
- HPN424 In Part 2 (Dose Expansion)
-
Los Angeles, California
- +14 more
Jan 20, 2023
Prospective Androgen Receptor Signaling Inhibitors Resistance
Not yet recruiting
- Prostate Cancer
- +3 more
- (no location specified)
Nov 15, 2023